Both in Pharmaceuticals
Phathom Pharmaceuticals vs Relmada Therapeutics
Over the past year PHAT returned −57.9% and RLMD returned +50.5%; their daily moves had a correlation of 0.21.
PHAT −57.9% RLMD +50.5%Growth of $1, one year, split-adjusted
| Metric | PHAT | RLMD |
|---|---|---|
| Price | $5.68 | $4.17 |
| Market cap | $461.7M | $444.8M |
| Today | −1.05% | −2.34% |
| 1 month | −16.2% | +27.1% |
| 6 months | −55.2% | −46.9% |
| Year to date | −65.8% | −13.7% |
| 1 year | −58.6% | +89.5% |
| Revenue growth (YoY) | +71.1% | — |
| Gross margin | 78.3% | — |
| Net margin | −16.4% | — |
| P/E (TTM) | — | — |
| Price / sales | 1.7× | — |
| Net cash | $17.6M | $217.7M |
| Dividend yield | — | — |
| Volatility (60d) | 72.0% | 60.0% |
| Short % of float | 17.5% | 14.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).